{"id":2129,"date":"2019-01-28T18:01:44","date_gmt":"2019-01-28T18:01:44","guid":{"rendered":"https:\/\/scda.dojiggyengage.com\/?p=2129"},"modified":"2019-01-28T18:01:44","modified_gmt":"2019-01-28T18:01:44","slug":"emmaus-life-sciences-launches-its-commercial-co-payment-assistance-program-for-endari","status":"publish","type":"post","link":"https:\/\/www.sicklecelldisease.org\/2019\/01\/28\/emmaus-life-sciences-launches-its-commercial-co-payment-assistance-program-for-endari\/","title":{"rendered":"Emmaus Life Sciences Launches Its Commercial Co-Payment Assistance Program for Endari\u2122"},"content":{"rendered":"<p>TORRANCE, Calif., Jan. 28, 2019 \/PRNewswire\/ \u2014 Emmaus Life Sciences, Inc.\u00a0(Emmaus), a leader in sickle cell disease treatment, announced today that it will provide financial assistance to help eligible patients afford their monthly co-payment for Endari\u2122 (L-glutamine oral powder) [1] . The program is limited to financially eligible patients covered by commercial insurance.<\/p>\n<div id=\"non-chrome\">\n<div class=\"lame-content-wrapper\">\n<div id=\"content-hole\">\n<article id=\"article\">\n<div id=\"article-meat\">\n<div id=\"article-body\">\nA significant number of individuals with sickle cell disease are covered by commercial insurance. In some cases, patients may have difficulty affording the monthly co-payment amount.<br \/>\nMark Diamond, Emmaus\u2019 Vice President of Commercialization, commented: \u201cWe are committed to removing barriers between patients and Endari \u2013 giving a greater number of patients access to our effective treatment for sickle cell disease.\u201d<br \/>\nClick\u00a0<a href=\"https:\/\/www.marketwatch.com\/press-release\/emmaus-life-sciences-launches-its-commercial-co-payment-assistance-program-for-endaritm-2019-01-28\">here<\/a>\u00a0to read the full press release.<br \/>\n<strong><em>Sickle Cell Disease Association of America, Inc. (SCDAA) in no way endorses any medications, treatments, clinical trials, or studies reported through Get Connected. Information is provided to keep the readers informed. Because the manifestations and severity of sickle cell vary among individuals, personalized medical management is essential. Therefore, it is strongly recommended that all drugs and treatments be discussed with the reader\u2019s physician(s) for proper evaluation and treatment.<\/em><\/strong>\n<\/div>\n<\/div>\n<\/article>\n<\/div>\n<\/div>\n<\/div>\n<div id=\"pe-main\">\n<div id=\"pe-content\" class=\"pe-single\">\n<div id=\"pe-content-in\" class=\"container-fluid\">\n<div class=\"row\">\n<div id=\"pe-content-wrapp\" class=\"col-md-12 col-md-push-0\">\n<div class=\"pe-article clearfix post-4049 event type-event status-publish hentry event_cat-webinar\">\n<div class=\"pe-article-content\">\n<div id=\"vsel\">\n<div class=\"vsel-image-info\"><\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>TORRANCE, Calif., Jan. 28, 2019 \/PRNewswire\/ \u2014 Emmaus Life Sciences, Inc.\u00a0(Emmaus), a leader in sickle cell disease treatment, announced today that it will provide financial assistance to help eligible patients afford their monthly co-payment for Endari\u2122 (L-glutamine oral powder) [1] . The program is limited to financially eligible patients covered by commercial insurance. A significant [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":1885,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-2129","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-uncategorized"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v24.0 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Emmaus Life Sciences Launches Its Commercial Co-Payment Assistance Program for Endari\u2122 - Sickle Cell Disease Association of America Inc.<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.sicklecelldisease.org\/2019\/01\/28\/emmaus-life-sciences-launches-its-commercial-co-payment-assistance-program-for-endari\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Emmaus Life Sciences Launches Its Commercial Co-Payment Assistance Program for Endari\u2122 - Sickle Cell Disease Association of America Inc.\" \/>\n<meta property=\"og:description\" content=\"TORRANCE, Calif., Jan. 28, 2019 \/PRNewswire\/ \u2014 Emmaus Life Sciences, Inc.\u00a0(Emmaus), a leader in sickle cell disease treatment, announced today that it will provide financial assistance to help eligible patients afford their monthly co-payment for Endari\u2122 (L-glutamine oral powder) [1] . The program is limited to financially eligible patients covered by commercial insurance. A significant [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.sicklecelldisease.org\/2019\/01\/28\/emmaus-life-sciences-launches-its-commercial-co-payment-assistance-program-for-endari\/\" \/>\n<meta property=\"og:site_name\" content=\"Sickle Cell Disease Association of America Inc.\" \/>\n<meta property=\"article:published_time\" content=\"2019-01-28T18:01:44+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.sicklecelldisease.org\/wp-content\/uploads\/2019\/02\/Emmaus-inthenews-header.png\" \/>\n\t<meta property=\"og:image:width\" content=\"800\" \/>\n\t<meta property=\"og:image:height\" content=\"250\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"admin\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"admin\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.sicklecelldisease.org\/2019\/01\/28\/emmaus-life-sciences-launches-its-commercial-co-payment-assistance-program-for-endari\/\",\"url\":\"https:\/\/www.sicklecelldisease.org\/2019\/01\/28\/emmaus-life-sciences-launches-its-commercial-co-payment-assistance-program-for-endari\/\",\"name\":\"Emmaus Life Sciences Launches Its Commercial Co-Payment Assistance Program for Endari\u2122 - Sickle Cell Disease Association of America Inc.\",\"isPartOf\":{\"@id\":\"https:\/\/www.sicklecelldisease.org\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/www.sicklecelldisease.org\/2019\/01\/28\/emmaus-life-sciences-launches-its-commercial-co-payment-assistance-program-for-endari\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/www.sicklecelldisease.org\/2019\/01\/28\/emmaus-life-sciences-launches-its-commercial-co-payment-assistance-program-for-endari\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.sicklecelldisease.org\/wp-content\/uploads\/2019\/02\/Emmaus-inthenews-header.png\",\"datePublished\":\"2019-01-28T18:01:44+00:00\",\"dateModified\":\"2019-01-28T18:01:44+00:00\",\"author\":{\"@id\":\"https:\/\/www.sicklecelldisease.org\/#\/schema\/person\/efc0c6b0f986827becc4515dd736f366\"},\"breadcrumb\":{\"@id\":\"https:\/\/www.sicklecelldisease.org\/2019\/01\/28\/emmaus-life-sciences-launches-its-commercial-co-payment-assistance-program-for-endari\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.sicklecelldisease.org\/2019\/01\/28\/emmaus-life-sciences-launches-its-commercial-co-payment-assistance-program-for-endari\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.sicklecelldisease.org\/2019\/01\/28\/emmaus-life-sciences-launches-its-commercial-co-payment-assistance-program-for-endari\/#primaryimage\",\"url\":\"https:\/\/www.sicklecelldisease.org\/wp-content\/uploads\/2019\/02\/Emmaus-inthenews-header.png\",\"contentUrl\":\"https:\/\/www.sicklecelldisease.org\/wp-content\/uploads\/2019\/02\/Emmaus-inthenews-header.png\",\"width\":800,\"height\":250},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.sicklecelldisease.org\/2019\/01\/28\/emmaus-life-sciences-launches-its-commercial-co-payment-assistance-program-for-endari\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.sicklecelldisease.org\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Emmaus Life Sciences Launches Its Commercial Co-Payment Assistance Program for Endari\u2122\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.sicklecelldisease.org\/#website\",\"url\":\"https:\/\/www.sicklecelldisease.org\/\",\"name\":\"Sickle Cell Disease Association of America Inc.\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.sicklecelldisease.org\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.sicklecelldisease.org\/#\/schema\/person\/efc0c6b0f986827becc4515dd736f366\",\"name\":\"admin\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.sicklecelldisease.org\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/2b80c3a97c5df05f644e48a1b6c6a1f0?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/2b80c3a97c5df05f644e48a1b6c6a1f0?s=96&d=mm&r=g\",\"caption\":\"admin\"},\"url\":\"https:\/\/www.sicklecelldisease.org\/author\/admin\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Emmaus Life Sciences Launches Its Commercial Co-Payment Assistance Program for Endari\u2122 - Sickle Cell Disease Association of America Inc.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.sicklecelldisease.org\/2019\/01\/28\/emmaus-life-sciences-launches-its-commercial-co-payment-assistance-program-for-endari\/","og_locale":"en_US","og_type":"article","og_title":"Emmaus Life Sciences Launches Its Commercial Co-Payment Assistance Program for Endari\u2122 - Sickle Cell Disease Association of America Inc.","og_description":"TORRANCE, Calif., Jan. 28, 2019 \/PRNewswire\/ \u2014 Emmaus Life Sciences, Inc.\u00a0(Emmaus), a leader in sickle cell disease treatment, announced today that it will provide financial assistance to help eligible patients afford their monthly co-payment for Endari\u2122 (L-glutamine oral powder) [1] . The program is limited to financially eligible patients covered by commercial insurance. A significant [&hellip;]","og_url":"https:\/\/www.sicklecelldisease.org\/2019\/01\/28\/emmaus-life-sciences-launches-its-commercial-co-payment-assistance-program-for-endari\/","og_site_name":"Sickle Cell Disease Association of America Inc.","article_published_time":"2019-01-28T18:01:44+00:00","og_image":[{"width":800,"height":250,"url":"https:\/\/www.sicklecelldisease.org\/wp-content\/uploads\/2019\/02\/Emmaus-inthenews-header.png","type":"image\/png"}],"author":"admin","twitter_card":"summary_large_image","twitter_misc":{"Written by":"admin","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.sicklecelldisease.org\/2019\/01\/28\/emmaus-life-sciences-launches-its-commercial-co-payment-assistance-program-for-endari\/","url":"https:\/\/www.sicklecelldisease.org\/2019\/01\/28\/emmaus-life-sciences-launches-its-commercial-co-payment-assistance-program-for-endari\/","name":"Emmaus Life Sciences Launches Its Commercial Co-Payment Assistance Program for Endari\u2122 - Sickle Cell Disease Association of America Inc.","isPartOf":{"@id":"https:\/\/www.sicklecelldisease.org\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.sicklecelldisease.org\/2019\/01\/28\/emmaus-life-sciences-launches-its-commercial-co-payment-assistance-program-for-endari\/#primaryimage"},"image":{"@id":"https:\/\/www.sicklecelldisease.org\/2019\/01\/28\/emmaus-life-sciences-launches-its-commercial-co-payment-assistance-program-for-endari\/#primaryimage"},"thumbnailUrl":"https:\/\/www.sicklecelldisease.org\/wp-content\/uploads\/2019\/02\/Emmaus-inthenews-header.png","datePublished":"2019-01-28T18:01:44+00:00","dateModified":"2019-01-28T18:01:44+00:00","author":{"@id":"https:\/\/www.sicklecelldisease.org\/#\/schema\/person\/efc0c6b0f986827becc4515dd736f366"},"breadcrumb":{"@id":"https:\/\/www.sicklecelldisease.org\/2019\/01\/28\/emmaus-life-sciences-launches-its-commercial-co-payment-assistance-program-for-endari\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.sicklecelldisease.org\/2019\/01\/28\/emmaus-life-sciences-launches-its-commercial-co-payment-assistance-program-for-endari\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.sicklecelldisease.org\/2019\/01\/28\/emmaus-life-sciences-launches-its-commercial-co-payment-assistance-program-for-endari\/#primaryimage","url":"https:\/\/www.sicklecelldisease.org\/wp-content\/uploads\/2019\/02\/Emmaus-inthenews-header.png","contentUrl":"https:\/\/www.sicklecelldisease.org\/wp-content\/uploads\/2019\/02\/Emmaus-inthenews-header.png","width":800,"height":250},{"@type":"BreadcrumbList","@id":"https:\/\/www.sicklecelldisease.org\/2019\/01\/28\/emmaus-life-sciences-launches-its-commercial-co-payment-assistance-program-for-endari\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.sicklecelldisease.org\/"},{"@type":"ListItem","position":2,"name":"Emmaus Life Sciences Launches Its Commercial Co-Payment Assistance Program for Endari\u2122"}]},{"@type":"WebSite","@id":"https:\/\/www.sicklecelldisease.org\/#website","url":"https:\/\/www.sicklecelldisease.org\/","name":"Sickle Cell Disease Association of America Inc.","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.sicklecelldisease.org\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.sicklecelldisease.org\/#\/schema\/person\/efc0c6b0f986827becc4515dd736f366","name":"admin","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.sicklecelldisease.org\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/2b80c3a97c5df05f644e48a1b6c6a1f0?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/2b80c3a97c5df05f644e48a1b6c6a1f0?s=96&d=mm&r=g","caption":"admin"},"url":"https:\/\/www.sicklecelldisease.org\/author\/admin\/"}]}},"_links":{"self":[{"href":"https:\/\/www.sicklecelldisease.org\/wp-json\/wp\/v2\/posts\/2129","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.sicklecelldisease.org\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.sicklecelldisease.org\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.sicklecelldisease.org\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.sicklecelldisease.org\/wp-json\/wp\/v2\/comments?post=2129"}],"version-history":[{"count":0,"href":"https:\/\/www.sicklecelldisease.org\/wp-json\/wp\/v2\/posts\/2129\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.sicklecelldisease.org\/wp-json\/wp\/v2\/media\/1885"}],"wp:attachment":[{"href":"https:\/\/www.sicklecelldisease.org\/wp-json\/wp\/v2\/media?parent=2129"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.sicklecelldisease.org\/wp-json\/wp\/v2\/categories?post=2129"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.sicklecelldisease.org\/wp-json\/wp\/v2\/tags?post=2129"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}